# Why Novo Nordisk’s Ozempic and Wegovy Cost Less Abroad – Novo Nordisk CEO faces questioning by senators regarding the cost disparity of Ozempic and Wegovy overseas. – American diabetes patients pay significantly more for these medications compared to other countries. – The company attributes the price difference to the complexity of the U.S. healthcare system. – Novo Nordisk commits to working with lawmakers to address the issue. Novo Nordisk’s CEO recently found himself in the hot seat as he was pressed by senators from different states regarding the significantly lower costs of popular diabetes medications, Ozempic and Wegovy, in overseas markets. American patients have long been burdened with exorbitant prices for these life-saving drugs compared to patients in other countries. The company’s top executive highlighted the intricacies of the U.S. healthcare system as a primary reason for the pricing disparities. However, Novo Nordisk has expressed willingness to collaborate with legislators to find solutions that could potentially make these medications more affordable for those in need. ### Hot Take: It is encouraging to see Novo Nordisk engaging with lawmakers and showing a commitment to addressing the concerns raised about the high costs of Ozempic and Wegovy in the U.S. Hopefully, this dialogue will lead to tangible actions that will make these vital medications more accessible to all who require them. **Weight Loss Disclaimer: Our personalized weight loss plans are designed to support your overall well-being. Always consult with a healthcare provider before starting any new weight loss program.** Contact Mindful Evolution today for personalized weight loss support! Reach out to us through our website https://yourmindfulevolution.com or give us a call or text at 954-639-9960. Ask about our telehealth services available in Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, North Carolina, New York, South Carolina, Tennessee, Texas, and Virginia.